White matter abnormalities in primary Sjögren syndrome

QJM: An International Journal of Medicine

Volumn 105, Issue 5, 2012, Pages 433-443

  Akasbi, M ^a   Berenguer, J ^b   Saiz, A ^c   Brito Zeron P ^a   Perez De Lis M ^c   Bove A ^a   Diaz Lagares, C ^a   Retamozo, S ^a   Blanco, Y ^c   Perez Alvarez, R ^c   Bosch, X ^d   Siso A ^a   Graus, F ^c   Ramos Casals, M ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b Center of Imaging Diagnosis   (Spain)

^c HOSPITAL DO MEIXOEIRO   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BRAIN REGION; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DEMYELINATING DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SJOEGREN SYNDROME; SYMPTOM; WHITE MATTER;

EID: 84859998241     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcr218     Document Type: Article

References (47)

1. Fox RI. Sjogren's syndrome. Lancet 2005; 366:321-31.
2. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern Med 2004; 164:1275-84.
3. Ramos-Casals M, Tzioufas AG, Font J. Primary Sjogren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis 2005; 64:347-54.
4. Ramírez M, Ramos-Casals M, Graus F. Central nervous system involvement in primary Sjögren syndrome. Med Clin 2009; 133:349-59.
5. Delalande S, de Seze J, Fauchais AL, Hachulla E, Stojkovic T, Ferriby D, et al. Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine 2004; 83:280-91.
6. Charil A, Yousry TA, Rovaris M, Barkhof F, De Stefano N, Fazekas F, et al. MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol 2006; 5:841-52.
7. Massara A, Bonazza S, Castellino G, Caniatti L, Trotta F, Borrelli M, et al. Central nervous system involvement in Sjögren's syndrome: unusual, but not unremarkable- clinical, serological characteristics and outcomes in a large cohort of Italian patients. Rheumatology 2010; 49:1540-9.
8. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61:554-8.
9. Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J, et al. GEMESS Study Group. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine 2008; 87:210-9.
10. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjögren M, et al. European Task Force on Age-Related White Matter Changes. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001; 32:1318-22.
11. Vernooij MW, Ikram MA, Tanghe HL, Vincent AJ, Hofman A, Krestin GP, et al. Incidental findings on brain MRI in the general population. N Engl J Med 2007; 357:1821-8.
12. Okuda DT, Mowry EM, Beheshtian A, Waubant E, Baranzini SE, Goodin DS, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 2009; 72:800-5.
13. Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120:2059-69.
14. Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Wallace DJ, et al. Systemic Lupus International Collaborating Clinics (SLICC). Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2010; 69:529-35.
15. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50:121-7.
16. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-87.
17. Pérez-De-Lis M, Akasbi M, Sisó A, Diez-Cascon P, Brito-Zerón P, Diaz-Lagares C, et al. Cardiovascular risk factors in primary Sjögren's syndrome: a case-control study in 624 patients. Lupus 2010; 19:941-8.
18. Chai J, Logigian EL. Neurological manifestations of primary Sjogren's syndrome. Curr Opin Neurol 2010; 23:509-13.
19. Morgen K, McFarland HF, Pillemer SR. Central nervous system disease in primary Sjogrens syndrome: the role of magnetic resonance imaging. Semin Arthritis Rheum 2004; 34:623-30.
20. Andonopoulos AP, Lagos G, Drosos AA, Moutsopoulos HM. The spectrum of neurological involvement in Sjögren's syndrome. Br J Rheumatol 1990; 29:21-3.
21. Okuda DT. Unanticipated demyelinating pathology of the CNS. Nat Rev Neurol 2009; 5:591-7.
22. Enzinger C, Fazekas F, Ropele S, Schmidt R. Progression of cerebral White matter lesions - clinical and radiological considerations. J Neurol Sci 2007; 257:5-10.
23. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010; 9:689-701.
24. Chard D, Miller D. Is multiple sclerosis a generalized disease of the central nervous system? An MRI perspective. Curr Opin Neurol 2009; 22:214-8.
25. Alexander EL, Beall SS, Gordon B, Selnes OA, Yannakakis GD, Patronas N, et al. Magnetic resonance imaging of cerebral lesions in patients with the Sjögren syndrome. Ann Intern Med 1988; 108:815-23.
26. Pierot L, Sauve C, Leger JM, Martin N, Koeger AC, Wechsler B, et al. Asymptomatic cerebral involvement in Sjögren's syndrome: MRI findings of 15 cases. Neuroradiology 1993; 35:378-80.
27. Escudero D, Latorre P, Codina M, Coll-Cantí J, Coll J. Central nervous system disease in Sjögren's syndrome. Ann Med Interne 1995; 146:239-42.
28. Tajima Y, Mito Y, Owada Y, Tsukishima E, Moriwaka F, Tashiro K. Neurological manifestations of primary Sjögren's syndrome in Japanese patients. Intern Med 1997; 36:690-3.
29. Govoni M, Bajocchi G, Rizzo N, Tola MR, Caniatti L, Tugnoli V, et al. Neurological involvement in primary Sjögren's syndrome: clinical and instrumental evaluation in a cohort of Italian patients. Clin Rheumatol 1999; 18:299-303.
30. Coates T, Slavotinek JP, Rischmueller M, Schultz D, Anderson C, Dellamelva M, et al. Cerebral white matter lesions in primary Sjögren's syndrome: a controlled study. J Rheumatol 1999; 26:1301-5.
31. Belin C, Moroni C, Caillat-Vigneron N, Debray M, Baudin M, Dumas JL, et al. Central nervous system involvement in Sjögren's syndrome: evidence from neuropsychological testing and HMPAO-SPECT. Ann Med Interne 1999; 150:598-604.
32. Lafitte C, Amoura Z, Cacoub P, Pradat-Diehl P, Picq C, Salachas F, et al. Neurological complications of primary Sjögren's syndrome. J Neurol 2001; 248:577-84.
33. Mataró M, Escudero D, Ariza M, Sánchez-Ojanguren J, Latorre P, Junqué C, et al. Magnetic resonance abnormalities associated with cognitive dysfunction in primary Sjögren syndrome. J Neurol 2003; 250:1070-6.
34. Le Guern V, Belin C, Henegar C, Moroni C, Maillet D, Lacau C, et al. Cognitive function and 99mTc-ECD brain SPECT are significantly correlated in patients with primary Sjögren syndrome: a case-control study. Ann Rheum Dis 2010; 69:132-7.
35. Alhomoud IA, Bohlega SA, Alkawi MZ, Alsemari AM, Omer SM, Alsenani FM. Primary Sjogren's syndrome with central nervous system involvement. Saudi Med J 2009; 30:1067-72.
36. Gono T, Kawaguchi Y, Katsumata Y, Takagi K, Tochimoto A, Baba S, et al. Clinical manifestations of neurological involvement in primary Sjögren's syndrome. Clin Rheumatol 2011; 30:485-90.
37. Harboe E, Beyer MK, Greve OJ, Gøransson LG, Tjensvoll AB, Kvaløy JT, et al. Cerebral white matter hyperintensities are not increased in patients with primary Sjögren's syndrome. Eur J Neurol 2009; 16:576-81.
38. Sachdev P, Wen W, Chen X, Brodaty H. Progression of white matter hyperintensities in elderly individuals over 3 years. Neurology 2007; 68:214-22.
39. Veglio F, Paglieri C, Rabbia F, Bisbocci D, Bergui M, Cerrato P. Hypertension and cerebrovascular damage. Atherosclerosis 2009; 205:331-41.
40. Bokura H, Yamaguchi S, Iijima K, Nagai A, Oguro H. Metabolic syndrome is associated with silent ischemic brain lesions. Stroke 2008; 39:1607-9.
41. den Heijer T, Launer LJ, Prins ND, van Dijk EJ, Vermeer SE, Hofman A, et al. Association between blood pressure, white matter lesions, and atrophy of the medial temporal lobe. Neurology 2005; 64:263-7.
42. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347:1141-5.
43. Schmidt R, Scheltens P, Erkinjuntti T, Pantoni L, Markus HS, Wallin A, et al. White matter lesion progression: a surrogate endpoint for trials in cerebral small-vessel disease. Neurology 2004; 63:139-44.
44. Vrethem M, Ernerudh J, Lindström F, Skogh T. Immunoglobulins within the central nervous system in primary Sjögren's syndrome. J Neurol Sci 1990; 100:186-92.
45. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 2010; 341:c3666.
46. Ramos-Casals M, Tzioufas AG, Stone JH, Sisó A, Bosch X. Treatment of primary Sjögren syndrome: a systematic review. JAMA 2010; 304:452-60.
47. Hawker K. B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data. Curr Opin Neurol 2008; 21:S19-25.